Phenolic compounds from Diarthron lessertii: isolation, cytotoxicity, and interaction with cancer signaling pathway, FOXO3a Authors: Hussein Biganeh, Morteza Sadeghi, Mehran Miroliaei, Mahnaz Khanavi, Mustafa Ghanadian Published: 2026 ABSTRACT Background and purpose:Natural products are valuable sources of anticancer agents. This study investigated the phytochemical composition of Diarthron lessertii shoot extract and evaluated the anticancer potential of its isolated phenolic constituents.Experimental approach:Phenolic compounds were isolated using chromatographic techniques and identified by one- and two-dimensional NMR spectroscopy and ESI-MS analysis. Cytotoxicity against HeLa cervical cancer cells was assessed using the MTT assay. A luciferase reporter assay evaluated the effect of the most active compound on FOXO3a was examined through molecular docking.Findings/Results:Nine phenolic compounds were isolated and characterized from D. lessertii, including two lignans (epinortrachelogenin and isolariciresinol), one biflavonoid (stelleranol), one bicoumarin (daphnoretin), and five flavonoids (genkwanin, apigenin 7,4’-dimethyl ether, naringenin, apigenin, and dihydrokaempferol). Among the isolated compounds, epinortrachelogenin (compound 1) showed the strongest cytotoxic activity against HeLa cells, with an IC50 value of 80.37 ± 4.72 μM. In luciferase assays, compound 1 selectively activated FOXO3a, reaching 2274 relative luminescence units at 100 pM. Molecular docking further supported these findings, revealing favorable binding of compound 1 within the FOXO3a binding pocket.Conclusion and implications:Epinortrachelogenin exhibited notable cytotoxicity and selective FOXO3a activation, supported by docking analysis. These findings identify this lignan as a promising lead compound for the development of FOXO3a-targeted anticancer agents. INTRODUCTION For decades, natural products have captured the spotlight in drug discovery, providing a variety of scaffolds with remarkable biological effects. Among them, phenolic compounds hold a special place due to their broad range of pharmacological properties, including antioxidant, anti-inflammatory, and antiproliferative effects(1). Lignans, coumarins, and flavonoids are important classes of phenolics, capable of modulating cellular function by intervening in cellular pathways(23). Therefore, their ability to interact with transcription factors, enzymes, and signaling proteins makes them potential contenders in drug development, particularly in cancer therapy, where the efficacy and safety issues of current treatment strategies highlight the urgent need for new therapeutic approaches(45). The Thymelaeaceae, a family (order: Malvales) of cosmopolitan trees and perennial plants, encompasses 50 genera and approximately 891 species and is a rich source of phytochemicals, particularly cytotoxic terpenoids and lignans(6). Plant species from this family have traditionally been used for their health-beneficial effects and have attracted scientific attention for their rich phytochemical diversity(78). Diarthron lessertii, a species native to Iran, is one of the plant species that, despite its history of traditional use and its potential for pharmacologically active compounds, has been scarcely investigated(9). A critical gap exists in linking the phytochemical profile of D. lessertii with molecular targets relevant to cancer biology. Although toxic compounds have been reported from this plant and related species, the phenolic constituents and their toxicity have not been fully investigated(10). In this context, one promising target is the transcription factor Forkhead box O (FOXO) 3a, a member of the forkhead box O family. The FOXO transcription factors play a critical role in tumor suppression across a variety of malignancies by regulating the expression of pro-apoptotic genes, including death receptor ligands such as Fas ligand (FasL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)(11). When the FOXO function is impaired, apoptosis is inhibited, resulting in abnormal cell survival and the development of cancer(12). Since this pathway has an important role in cancer progression, identifying selective modulators is highly significant. Addressing this gap, our research focuses on the isolation of phenolic compounds from D. lessertii, investigating their in vitro cytotoxicity against the HeLa cancer cell line, and evaluating the screened compounds for their ability to interact with FOXO protein using a luciferase reporter assay. MATERIALS AND METHODS General experimental procedures Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker 400 spectrometer (Bruker, Billerica, MA, USA) operating at 400.13 MHz for 1H and 100.62 MHz for 13C, using dimethyl sulfoxide-d6 (DMSO-d6; δh 2.50, δc 39.52) as the solvent. Electrospray ionization mass spectrometry (ESI-MS) data were obtained using a SCIEX 3200 QTRAP Mass Spectrometry system (SCIEX, Framingham, MA, USA). Chromatographic separations were performed using silica gel (Merck, Darmstadt, Germany; 40-63 μm, 1 × 60 cm i.d. column), Sephadex LH-20 (Sigma-Aldrich, St Louis, mO, USA; 1 × 60 cm i.d column), polyamide (Sigma Aldrich, St. Louis, MO, USA; 1 × 16 cm i.d. open column), and reversed-phase high-pressure liquid chromatography (RP-HPLC, YMC Co., Ltd., Kyoto, Japan; 4.6 × 25 cm, 5 μm) on a Shimpack C18 column (Shimadzu, Kyoto, Japan) under conventional conditions. Thin-layer chromatography (TLC) plates (silica gel 60 GF254, Merck, Darmstadt, Germany) were used for monitoring, with UV light (254 nm) and cerium sulfate reagent for visualization. Plant material D. lessertii shoots were gathered from Mashhad, Iran (April 2022). Dr. Mohammadreza Joharchi recognized the plant’s botanical authenticity, and a specimen (Voucher No. SAM-2403) has been deposited in the Department of Pharmacognosy, Isfahan University of Medical Sciences, Iran. Extraction and isolation Powdered shoots (8 kg) were extracted with methanol using the percolation method for three weeks. The crude extract (1.2 kg) was concentrated under reduced pressure and fractionated by reversed-phase vacuum liquid chromatography (MeOH: H2O, 70:30). Liquid-liquid partitioning with ethyl acetate and brine was used to remove highly polar impurities. The ethyl acetate fraction was subjected to medium-pressure liquid chromatography (MPLC) on a normal silica gel column (4.9 × 92 cm, particle size 15-40 μm) with a chloroform-acetone gradient (0-50%), yielding several fractions. Subsequent separation was performed by Sephadex LH-20 (2 × 60 cm), polyamide SC6 (1 × 16 cm), and silica gel column chromatography (3 × 71 cm, particle size 40-63 μm), affording nine phenolic compounds. Final purification was achieved by RP-HPLC on a Shimpack C18 column (4.6 × 25 cm, particle size 5 μm) with a methanol-water gradient at a flow rate of 3 mL/min. Detection was carried out using UV absorbance at 254 nm (Fig. 1). The tree diagram of the extraction and isolation of purified compounds. VLC, Vacuum liquid chromatography; EtOAc, ethyl acetate; MPLC, medium-pressure liquid chromatography; CC, column chromatography. Cell viability MTT assay HeLa cervical cancer cells (Pasteur Institute, Iran) were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 100U/mL penicillin, and 100 μg/mL streptomycin at 37 °C in a humidified atmosphere containing 5% CO2. Cells (5 × 103 per well in 96- well plates) were treated with test compounds (0.1-200 μM) for 48 h. Doxorubicin (1 μM) was used as the positive control. Following treatment, MTT reagent (5 mg/mL stock in PBS) was added to each well at a volume of 20 μL, resulting in a final concentration of approximately 0.45 mg/mL, and incubated for 4 h. The resulting formazan crystals were dissolved in 150 μL DMSO, and absorbance was measured at 570 nm using a Bio-Rad microplate reader (Hercules, CA, USA). Cell viability was expressed relative to untreated controls, and IC50 values were calculated(1314). Assessment of FOXO3a pathway involvement HeLa cells (ATCC CCL-2) were seeded in white opaque 384-well plates (PerkinElmer, Waltham, Ma, USA) at a density of 0.0043 × 106 cells/well in 30 μL growth medium (DMEM with 10% FBS and 1% penicillin/streptomycin), as described in our previous study(15). The next day, medium was replaced with DMEM containing 1% FBS, and cells were transfected with 25-50 ng plasmid DNA per well using X-tremeGENE HP transfection reagent (Roche, Germany) following the manufacturer’s protocol optimized for 384-well format. Plasmids included a pathway-specific luciferase reporter for FOXO3a, together with the herpes simplex virus thymidine kinase promoter (pTK) empty vector control, obtained from commercial suppliers (Affymetrix, Santa Clara, CA, USA; Signosis, Santa Clara, CA, USA; MilliporeSigma, Burlington, MA, USA)(1316). Transfection efficiency controls included the pTK empty vector in every experiment to establish baseline luciferase activity. After 24-h transfection, cells were treated with test compounds. FOXO3a was assessed without an external inducer. After 4 to 6 h induction, cells were lysed with One-Glo luciferase assay system (Promega, Madison, WI, USA), and luminescence was measured using Glomax Multi+ detection system (Promega, Madison, WI, USA). Results were expressed as relative luminescence units (RLU)(17). Molecular docking Ligand structure was drawn in ChemSketch and energy-minimized in UCSF Chimera 1.7. Docking simulations were performed using AutoDock 4.2 against FOXO3a binding sites defined from published data(18). Binding energies and interaction profiles were analyzed with Discovery Studio. Docking score was expressed as predicted free binding energies (kcal/mol)(19). Statistical analysis Cell viability data from the MTT assay were analyzed using one-way analysis of variance (one-way ANOVA) followed by Dunnett’s multiple comparisons post hoc test to compare each treatment concentration with the corresponding vehicle (untreated) control. Doxorubicin was used as the positive control. All experiments were performed in triplicate (n = 3 independent biological replicates), and results are expressed as mean ± SD. P-values < 0.05 were considered statistically significant. Graphs and statistical analyses were performed using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA, version 10.4.1) RESULTS Structural elucidation of isolated metabolites Phytochemical analysis of D. lessertii yielded nine phenolic metabolites (Fig. 2). The structures of these metabolites were confirmed by NMR and ESI-MS, as detailed in the following spectral data: Compound 1: 1H-NMR (400.13 MHZ, DMSO-d6): δh 6.79 (brs, H-2, 1H), 6.80 (obs, H-5, 1H), 6.51 (d, J = 8 Hz, H-6, 1H), 2.57 (dd, J = 13.2 Hz, obs, H-7α, 1H), 2.88 (dd, J = 12.8 Hz, 3.2, H-7β, 1H), 2.61 (m, H-8, 1H), 4.01 (dd, J = 6.8 Hz, 2, H-9α, 1H), 3.76 (m, H-9β, 1H), 6.66 (brs, H-2’, 1H), 6.65 (d, J = 8 Hz, H-5’, 1H), 6.52 (d, J = 8 Hz, H-6’, 1H), 2.81 (dd, J = 14.4 Hz, obs, H-7’α, 1H), 2.94 (dd, J = 14.4 Hz, obs, H-7’β, 1H), 8.74 (s, 4-OH, 1H), 8.76 (s, 4’-OH, 1H), 3.77 (s, 3-OCH3, 3H), 3.74 (s, 3’-OCH3, 3H); 13C-NMR (100 MHz, DMSO-d6): δc 126.10 (C-1), 114.42 (C2), 146.71 (C-3), 145.02 (C-4), 114.79 (C-5), 120.34 (C-6), 30.89 (C-7), 48.29 (C-8), 68.30 (C-9), 129.57 (C-1’), 112.24 (C-2’), 147.40 (C-3’), 145.43 (C-4’), 115.31 (C-5’), 122.53 (C-6’), 37.22 (C-7’), 76.19 (C-8’), 177.40 (C-9’), 55.31 (3-OCH3), 55.31 (3’-OCH3); Negative ESIMS m/z 373.132 [M - H]-. The chemical structures of isolated compounds from Diarthron lessertii (Wikstr.) Kit Tan. Compound 2: 1H-NMR (400 MHz, DMSO-d6): δh6.61 (s, H-2, 1H), 6.15 (s, H-5, 1H), 2.77 (d, J = 8 Hz, H-7, 1H), 1.82 (m, H-8, 1H), 3.60 (dd, J = 11 Hz, 4.4, H-9α, 1H), 3.45 (dd, J = 11.0 Hz, 3.6, H-9β, 1H), 6.61 (s, H-2’, 1H), 6.70 (d, J = 8.0 Hz, H-5’, 1H), 6.50 (dd, J = 8.4 Hz, 2, H-6’, 1H), 3.71 (d, J = 3.4 Hz, H-7’, 1H), 1.65 (m, H-8’, 1H), 3.46 (d, J = 10.4 Hz, 3.6 Hz, H-9’α, 1H), 3.20 (dd, J = 10.4 Hz, H-9’β, 1H), 3.80 (s, 3-OMe, 3H), 3.85 (s, 4-OH, 1H), 3.79 (s, 3’-OMe, 3H), 3.85 (s, 4’-OH, 1H). 13C-NMR (100 MHz, DMSO-d6): δC 127.60 (C1), 112.23 (C2), 147.80 (C3), 145.06 (C4), 116.72 (C5), 137.59 (C6), 32.75 (C7), 39.50 (C8), 64.04 (C9), 133.10 (C1’), 113.65 (C2’), 145.95 (C3’), 144.50 (C4’), 115.73 (C5’), 121.90 (C6’), 46.36 (C7’), 49.06 (C8’), 60.19 (C9’), 55.80 (3-OCH3), 55.80 (3’-OCH3); negative ESIMS m/z 359.158 [M - H]-. Compound 3: 1H-NMR (400.13 MHZ, DMSO-d6): δh 6.84 (s, H-3, 1H), 6.37 (d, J = 2. Hz, H-6, 1H), 6.77 (d, J = 2.0 Hz, H-8, 1H), 7.97 (d, J = 8.8 Hz, H-2’, 1H), 6.95 (d, J = 8.8 Hz, H-3’, 1H), 6.95 (d, J = 8.8 Hz, H-5’, 1H), 7.97 (d, J = 8.8 Hz, H-6’, 1H), 12.96 (brs, 5-OH, 1H), 3.87 (s, 7-OCH3, 1H). 13C NMR (101 MHZ, DMSO-d6): δC 164.54 (C2), 103.46 (C3), 182.40 (C4), 157.69 (C4a), 161.79 (C5), 98.42 (C6), 165.59 (C7), 93.14 (C8), 105.12 (C8a), 121.51 (C1’), 129.03 (C2’), 116.45 (C3’), 161.65 (C4’), 116.45 (C5’), 129.03 (C6’), 56.54 (7-OCH3). Compound 4: 1H-NMR (400.13 MHZ, DMSO-d6): δH 6.96 (s, H-3, 1H), 6.38 (d, J = 2.0 Hz, H-6, 1H), 6.79 (d, J = 2.0 Hz, H-8, 1H), 8.07 (d, J = 8.8 Hz, H-2’, 1H), 7.13 (d, J = 8.8 Hz, H-3’, 1H), 7.13 (d, J = 8.8 Hz, H-5’, 1H), 8.07 (d, J = 8.8 Hz, H-6’, 1H), 12.91 (brs, 5-OH, 1H), 3.87 (s, 7-OCH3, 1H), 3.86 (s, 4’-OCH3, 1H). 13C-NMR (101 MHZ, DMSO-d6): δC 164.1 (C2), 104.16 (C3), 182.44 (C4), 157.74 (4a), 162.90 (C5), 98.51 (C6), 165.67 (C7), 93.20 (C8), 105.20 (8a), 123.16 (C1’), 128.86 (C2’), 115.07 (C3’), 161.65 (C4’), 115.07(C5’), 128.86 (C6’), 56.54 (7-OCH3), 56.04 (4’-OCH3). Compound 5: 1H-NMR (400 MHz, DMSO-d6): δH 5.43 (dd, J = 2.8 Hz, 12.8 Hz, H-2, 1H), 3.91 (obs., H-3α, 1H), 2.67 (obs., H-3β, 1H), 5.88 (s, H-6, 1H), 5.88 (s, H-8, 1H), 7.30 (d, J = 11.6 Hz, H-2’, 1H), 6.78 (d, J = 8.8 Hz, H-3’, 1H), 6.78 (d, J = 8.8 Hz, H-5’, 1H), 7.30 (d, J= 11.6 Hz, H-6’, 1H). 13C-NMR (100 MHz, DMSO-d6): δC 78.89 (C2), 42.46 (C3), 196.84 (C4), 163.41 (C4a), 163.96 (C5), 96.27 (C6), 167.14 (C7), 95.45 (C8), 102.25 (C8a), 129.34 (C1’), 128.78 (C2’), 115.64 (C3’), 158.21 (C4’), 115.64 (C5’), 128.78 (C6’). Compound 6: 1H-NMR (400 MHz, DMSO-d6): δh6.78 (s, H-3, 1H), 6.20 (d, J = 2 Hz, H-6, 1H), 6.49 (d, J = 2 Hz, H-8, 1H), 7.93 (d, J = 8.8 Hz, H-2’, 1H), 6.93 (d, J = 8.8 Hz, H-3’, 1H), 6.93 (d, J = 8.8 Hz, H-5’, 1H), 7.93 (d, J = 8.8 Hz, H-6’, 1H), 12.96 (s, 5-OH, 1H), 10.41 (bs, 7-OH, 1H). 13C-NMR (100 MHz, DMSO-d6): δC 164.22 (C2), 103.31 (C3), 182.22 (C4), 104.16 (C4a), 161.92 (C5), 99.31 (C6), 164.62 (C7), 94.44 (C8), 157.78 (C8a), 121.64 (C1’), 128.95 (C2’), 116.44 (C3’), 161.65 (C4’), 116.44 (C5’), 128.95 (C6’). Compound 7: 1H-NMR (400 MHz, DMSO-d6): δh 4.59 (dd, J = 11.51 Hz, 6.13 Hz, H-2, 1H), 5.05 (d, J = 11.4 Hz, H-3, 1H), 5.86 (d, J = 2.2 Hz, H-6, 1H), 5.92 (d, J = 2 Hz, H-8, 1H), 7.33 (d, J = 8.8 Hz, H-2’, 1H), 6.75 (d, J = 8.4 Hz, H-3’, 1H), 6.78 (d, J = 8.4 Hz, H-5’, 1H), 7.33(d, J = 8.8 Hz, H-6’, 1H), 5.83 (d, J = 6.10 Hz, 3-OH, 1H), 11.92 (s, 5-OH, 1H), 10.87 (bs, 7-OH, 1H), 9.59 (s, 4’-OH, 1H). 13C-NMR (100 MHz, DMSO-d6): δC 83.53 (C2), 72.09 (C3), 198.64 (C4), 101.12 (C4a), 163.95 (C5), 96.67 (C6), 167.45 (C7), 95.65 (C8), 163.24 (C8a), 128.22(C1’), 130.16 (C2’), 115.55 (C3’), 158.41 (C4’), 115.55 (C5’), 130.16 (C6’). Compound 8: 1H-NMR (400 MHz, DMSO-d6): δH 3.81 (3H, s, H-6-OMe), 6.37 (1H, d, J = 9.5 Hz, H-3), 6.83 (1H, s, H-8ʹ), 7.10 (1H, dd, J = 8.6 Hz, 2.5 Hz, H-6), 7.17 (1H, d, J = 2.4 Hz, H-8), 7.19 (1H, s, H-5ʹ), 7.70 (1H, d, J = 8.6 Hz, H-5), 7.86 (1H, s, H-4ʹ), 8.04 (1H, d, J = 9.6 Hz, H-4). 13C-NMR (100 MHz, DMSO-d6): δC 56.44(C-6-OMe), 103.20 (C-8ʹ), 104.41 (C-8), 109.71 (C-5ʹ), 113.85 (C-6), 114.31 (C-3), 114.81(C-10), 130.35 (C-5), 131.52 (C-4ʹ), 135.81(C-3ʹ),144.53 (C-4), 146.36 (C-6ʹ), 148.12 (C-9ʹ), 151.60 (C-7ʹ), 155.46 (C-9), 157.48 (C-2ʹ), 160.20 (C-2), and 160.44 (C-7). Negative ESIMS at m/z 351.057 [M - H]-. Compound 9: 1H-NMR (400 MHz, DMSO-d6): δH 4.86 (s, H-2, 1H), 3.96 (m, H-3, 1H), 2.43 (d, overlapped with the solvent signal, J = 17.6 Hz, H-4α, 1H), 2.37 (dd, J = 4.4 Hz, 17.2 Hz, H-4β, 1H), 5.69 (s, H-6, 1H), 6.58 (d, J = 8.8 Hz, H-2’, 1H), 6.50 (d, J = 8.8 Hz, H-3’, 1H), 6.50 (d, J = 8.8 Hz, H-5’, 1H), 6.58 (d, J = 8.8 Hz, H-6’, 1H), 5.97 (s, H-2’’, 1H), 6.04 (d, J = 2 Hz, H-6’’, 1H), 6.07 (d, J = 2 Hz, H-8’’, 1H), 7.09 (d, J = 8.8 Hz, H-10’’, 1H), 6.73 (d, J = 8.8 Hz, H-11’’, 1H), 6.73 (d, J = 8.8 Hz, H-13’’, 1H), 7.09 (d, J = 8.8 Hz, H-14’’, 1H), 6.53 (s, 3-OH), 9.23 (s, 4’-OH), 4.58 (d, J = 4 Hz, 3’’-OH, 1H), 11.28 (s, 5’’-OH, 1H), 11.28 (s, 7’’-OH, 1H), 9.57 (s, 12’’-OH, 1H). 13C-NMR (100 MHz, DMSO-d6): δC 80.45 (C2), 63.74 (C3), 27.39 (C4), 108.93 (C4a), 187.50 (C5), 101.20 (C6), 168.88 (C7), 85.71 (C8), 158.64 (C8a), 128.78 (C1’), 127.67 (C2’), 114.71 (C3’), 156.84 (C4’), 114.71 (C5’), 127.67 (C6’), 90.42 (C2’’), 80.45 (C3’’), 191.30 (C4’’), 100.38 (C4’’a), 163.93 (C5’’), 97.30 (C6’’), 168.19 (C7’’), 96.86 (C8’’), 160.91 (C8’’a), 122.72 (C9’’), 130.36 (C10’’), 115.11 (C11’), 158.66 (C12’’), 115.11 (C13’’), 130.36 (C14’’); negative ESIMS m/z 557.102 [M - H]-. The effect of isolated compounds on cell viability Among the nine phenolic compounds isolated from D. lessertii, compound 1 (epinortrachelogenin) exhibited a more cytotoxic effect against HeLa cervical cancer cells, with concentration-dependent reduction in cell viability and an IC50 value of 80.37 ± 4.72 μM. In comparison, the positive control doxorubicin (1 μM) reduced cell viability to 44.22 ± 1.13% (not shown in the graphs), confirming assay validity. In contrast, compounds 2, 3, 4, 6, 7, and 9 showed less cytotoxicity, with significant cytotoxicity at the highest concentration (200 μM). The remaining compounds (5 and 8) displayed no significant cytotoxicity within the tested concentration range (Fig. 3). Cytotoxic effects of the isolated compounds against HeLa cancer cells determined by the MTT assay. Cells were treated in triplicate with different concentrations of each compound (1, 10, 100, and 200 μM) for 48 h. (A-I) correspond to compounds 1-9, respectively. Untreated cells served as the negative control. *P < 0.05, **P < 0.01, and ***P < 0.001 indicate significant differences in comparison with the control group. Luciferase assay for an array of cancer signaling pathways Based on the MTT assay, compound 1 was evaluated for cytotoxicity and its effect on FOXO3a, as described in the experimental section. The results indicated that compound 1 activated FOXO3a as an apoptotic mediator, reaching 2274 RLU at 100 μM (Fig. 4). Concentration-response effect of compound 1 on FOXO gene expression. Molecular docking assessment Molecular docking simulations supported the findings. Compound 1 showed strong binding affinity to FOXO3a, with a predicted free binding energy of -5.19 kcal/mol. The ligand formed stable hydrogen bonds and hydrophobic interactions within the FOXO3a binding pocket, consistent with its observed biological activity (Fig. 5A-D). (A) The architecture of the complex formed by the interaction of compound 1 with FOXO; (B) 2D interaction of compound 1 with FOXO3a; (C) 3D structure of FOXO3a-compound 1 complex; (D) H-bond structure of FOXO3a-compound 1 complex. DISCUSSION In a phytochemical analysis of D. lessertii, nine phenolics, including two lignans(12), five flavonoids(34567), one bicoumarin(8), and one biflavonoid(9), were identified and extracted from this plant for the first time. Compound 1 showed a molecular formula of C20H22O7 aligned with negative ESI mass at m/z 373.1317 and NMR data. 13C-NMR and DEPT showed the presence of two oxymethyl groups at δC 56.08 (3ʹ-OMe) and 56.08 (3-OMe); three methylene carbons at δC 38.07 (C7ʹ), 32.00 (C7), with one oxygenated at 68.63 (C9); six olefin methine carbons at δC 111.92 (C2’), 114.58 (C5’), 123.09 (C6ʹ), 112.88 (C2), 114.99 (C5), 120.91 (C6), with one aliphatic at δC 48.81 (C8); eight quaternary carbons including four oxygenated olefin at δC 146.01 (C3ʹ), 145.19 (C4ʹ), 147.01 (C3), 145.16 (C4), two olefin at δC 126.34 (C1ʹ), 130.26 (C1), one carbonyl at 177.48 (C9’), and one oxygenated carbon at 76.56 (C8ʹ). 1H-NMR spectroscopy in the aromatic region showed two overlapped ABC systems, including [δh 6.64 (bs, H2ʹ, 1H), 6.54 (bd, J = 8.0 Hz, H5ʹ, 1H), 6.65 (d, J = 8.0 Hz, H6ʹ, 1H)], and [δh 6.64 (d, J = 2.4 Hz, H2, 1H), 6.82 (d, J = 7.6 Hz, H5, 1H), 6.52 (d, J = 7.6 Hz, H6, 1H)] related to two benzene rings substituted at 1, 3, and 4 positions. COSY correlation showed the spin system of H2(7)-H(8)-H2(9) proposing a dibenzylbutyrolactone derivative. Heteronuclear multiple bond correlation (HMBC) identified methoxy groups at C3ʹ and C3 and an oxygenated carbon at C8ʹ. This structure was previously reported from Bupleurum salicifolium as epinortrachelogenin(20). Compound 2 showed a negative ESI mass at m/z 359.1 [M-H]-. Apart from two methoxy groups at δc 55.61 and 55.62 ppm, the main core revealed 20 resonances in 13C-NMR associated with three methylenes at δc 32.8 (C7), with two external oxygenated ones at 62.1 (C9’), and 65.7 (C9); eight methines, including five aromatics at 113.65 (C2’), 114.5 (C5’), 121.9 (C6’), 110.6 (C6), and 115.8 (C3), and three aliphatics at 47.4 (C7’), 47.5 (C8’), and 39.5 (C8); seven quaternary olefinic carbons at 133.1 (C1’), 127.2 (C1), and 136.8 (C2), along with four oxygenated ones at 145.2 (C3’), 143.5 (C4’), 147.1 (C5), and 144.1 (C4). HMBC analysis located the methoxy groups and confirmed the structure as 3’,5-dimethoxy-2,7’-cyclolignan(21). Compounds 3-7 were identified as genkwanin (3)(22), apigenin 7,4’-dimethyl ether (4)(23), naringenin (5)(24), apigenin (6)(14), and dihydrokaempferol (7)(25), all featuring a flavonoid scaffold, while compound 8 was identified as daphnoretin(26), a bicumarin. Compound 9, with a negative molecular mass of 557.102 [M-H]- and 13C-NMR spectra data, was consistent with the molecular formula of C30H22O11. In the 13C-NMR spectrum, 26 distinct carbon resonances, with four peaks appearing as duplicates, are attributed to 14 methines: δc 101.20 (C6), 127.67 (C2’), 114.71 (C3’), 114.71 (C5’), 127.67 (C6’), 90.42 (C2’’), 97.30 (C6’’), 96.86 (C8’’), 130.36 (C10’’), 115.11 (C11’’), 115.11 (C13’’), 130.36 (C14’’) ppm, and one oxygen and hydroxy-bearing methine carbons at δc 80.45 (C2) and 63.74 (C3) ppm, respectively. In addition, one methylene: δc 27.39 (C4) ppm; 15 quaternary carbons: δc 108.93 (C4a), 168.88 (C7), 158.64 (C8a), 128.78 (C1’), 100.38 (C4’’a), 122.72 (C9’’) ppm; two carbonyls 187.50 (C5) and 191.30 (C4’’) ppm; and six single-bonded oxygenated carbons:85.71 (C8), 156.84 (C4’), 80.45 (C3’’), 163.93 (C5’’), 168.19 (C7’’), 160.91 (C8’’a), 158.66 (C12’’) were also observable. Heteronuclear single quantum coherence (HSQC) and HMBC analyses confirmed the structure as stelleranol(27). These classes of phytochemicals are consistent with the chemical diversity of the genera like Daphne, Stellera, and Wikstroemia in this family(728). The current findings obtained by MTT assay, among the isolated metabolites, compound 1 (epinortrachelogenin) exhibited the most cytotoxicity against HeLa cervical cancer cells. In contrast, other compounds displayed negligible activity under the same conditions. This differential activity highlights the importance of structural features in determining interactions with cellular targets. Considering the cytotoxic capability of lignans, Yao et al. reported that wikstromol, an isomer of compound 1 from Wikstroemia indica, inhibited the growth and migration of triple-negative breast cancer MDA-MB-231 cells by inducing apoptosis and suppressing the PI3K/Akt-NF-κB/MMP-9 signaling pathway(29). In addition, this dibenzyl-butyrolactone lignan-based compound showed anti-leukemic activity(30). In another study by Li and coworkers(31), arctigenin, a lignan with a dibenzylbutyrolactone structure, showed inhibitory activity on the proliferation of activated hepatic stellate cells by interfering with the FOXO3a pathway. Taken together, these studies, along with the findings of the present work, highlight the potential of this structural scaffold as a lead compound for developing cancer therapeutics. Considering the underlying mechanism, luciferase reporter assays revealed that compound 1 selectively activated FOXO3a, a transcription factor involved in apoptosis, oxidative stress response, and tumor suppression. This selectivity is important, as FOXO3a plays a crucial role in cell fate, and its activation typically results in enhanced apoptosis and inhibition of tumor progression(32). The molecular docking study further supports the findings of the experimental assays. Compound 1 demonstrated a favorable binding energy (-5.19 kcal/mol) within the FOXO3a binding pocket. The FOXO3a-compound 1 interactions were classified as van der Waals forces, π-π stacking interactions, and conventional hydrogen bonds. Specifically, residues Tyr206 and Asn210 were identified as forming hydrogen bonds with compound 1, while π-π stacking interactions were observed between Tyr206 and compound 1. In addition to these key interactions, the FOXO-compound 1 complex demonstrated seven van der Waals interactions, as depicted in Fig. 5. These findings are consistent with the experimental results. Although FOXO3a activation is associated with apoptosis, it is not sufficient to establish apoptosis induction conclusively. To further assess cellular processes, it is recommended to employ direct assays such as caspase-3/7 activity measurement, annexin V/propidium iodide (PI) staining, and poly (ADP-ribose) polymerase (PARP) cleavage. These methodologies provide a comprehensive evaluation of apoptosis and related cellular events. In addition, further studies should investigate the downstream molecular pathways regulated by FOXO3a activation and evaluate the in vivo relevance of these findings to strengthen the mechanistic understanding and therapeutic potential. Beyond the cytotoxicity of the isolated lignan, the identification of bioflavonoids is noteworthy, as they exhibit a broad spectrum of biological activities without displaying significant toxicity. These compounds are well established for their antioxidant, anti-inflammatory, anti-neurodegenerative, and regulatory effects, underscoring their potential for further exploration in future studies(28). CONCLUSION This study provides a comprehensive characterization of the phenolic profile of D. lessertii. Among the isolated compounds, epinortrachelogenin, a dibenzyl-butyrolactone lignan, exhibited selective FOXO3a activation with cytotoxic potential. Findings from the in vitro and in silico investigations provide insight into this lignan’s activity against the HeLa cancer cell line. The study results not only enrich our chemical knowledge of Thymelaeaceae metabolites but also identify a lead compound for anticancer drug discovery through FOXO3a modulation. However, to achieve a comprehensive understanding of this lignan’s safety and efficacy, further studies are warranted. Authors’ contributions H. Biganeh contributed to methodology and investigation and wrote the original draft. M. Sadeghi conducted the docking studies and wrote the original draft. M. Miroliaei and M. Khanavi supervised the study. M. Ghanadian conceptualized and supervised the study and contributed to the methodology. All authors have read and approved the finalized article. Each author has fulfilled the authorship criteria and affirmed that this article represents honest and original work. Conflict of interest statement The authors declared no conflict of interest in this study. AI declaration During the preparation of this work, the author(s) used ChatGPT (OpenAI) to improve the readability and language of the manuscript. After using this tool, the author(s) reviewed and edited the content and take full responsibility for the content of the publication. Also, AI-assisted design tools were employed for the preparation of the graphical abstract, followed by manual refinement by the authors. Data availability The data supporting the findings of this study are available from the corresponding author upon reasonable request. Researchers interested in accessing the data should contact the corresponding author to discuss the terms and conditions of data access.